Inactivation of tumor suppressors and inhibitory microenvironmental factors is necessary for breast cancer invasion; therefore, identifying those suppressors and factors is crucial not only to advancing our knowledge of breast cancer, but also to discovering potential therapeutic targets. By analyzing gene expression profiles of polarized and disorganized human mammary epithelial cells in a physiologically relevant three-dimensional (3D) culture system, we identified retinoid orphan nuclear receptor alpha (RORa) as a transcription regulator of semaphorin 3F (SEMA3F), a suppressive microenvironmental factor. We showed that expression of RORa was downregulated in human breast cancer tissue and cell lines, and that reduced mRNA levels of RORa and SEMA3F correlated with poor prognosis. Restoring RORa expression reprogrammed breast cancer cells to form noninvasiveness structures in 3D culture and inhibited tumor growth in nude mice, accompanied by enhanced SEMA3F expression. Inactivation of RORa in nonmalignant human mammary epithelial cells inhibited SEMA3F transcription and impaired polarized acinar morphogenesis. Using chromatin immunoprecipitation and luciferase reporter assays, we showed that transcription of SEMA3F is directly regulated by RORa. Knockdown of SEMA3F in RORa-expressing cancer cells rescued the aggressive 3D phenotypes and tumor invasion. These findings indicate that RORa is a potential tumor suppressor and inhibits tumor invasion by inducing suppressive cell microenvironment. Cancer Res; 72(7);
Introduction
The nuclear receptor superfamily contains a number of orphan receptors for which no ligand has been well characterized. Retinoid orphan nuclear receptor alpha (RORa) is a member of the orphan nuclear factor family and regulates gene expression by binding to ROR response elements (RORE; refs. 1, 2). Expression of RORa has been detected in multiple tissues and cells including brain, heart, skin, muscle, colon, lung, spleen, leukocytes, and mammary epithelial cells (1, (3) (4) (5) (6) (7) . This factor regulates various cell functions including differentiation, metabolism, inflammation, transformation, and circadian clock function (6, (8) (9) (10) . The RORa gene maps to 15q22.2, a region that is often deleted in cancer, thus RORa has been proposed to be inactivated during cancer development (11) . One recent study showed that phosphorylated RORa attenuates transcriptional activity of b-catenin and inhibits anchorage-independent growth of colon cancer cells, suggesting that RORa is a potential tumor suppressor in colon cancer (6) .
However, the function of RORa in breast cancer development and progression largely is unknown.
Mammary tissue morphogenesis and differentiation is controlled by various microenvironmental cues, including secretory factors, cell-extracellular matrix (ECM) and cell-cell contacts, as well as their downstream signals (12, 13) . These microenvironmental signals are often dysregulated during breast cancer development and progression, leading to disruption of tissue polarity, enhanced cell invasion, and metastasis (14) (15) (16) . To investigate how the microenvironmental cues contribute to breast cancer progression, Dr. Bissell's laboratory developed a three-dimensional (3D) culture model with HMT-3522 human breast cancer progression cell lines (S1, T4-2; ref. 17) . It has been shown that nonmalignant mammary epithelial cells maintain acinar structures and tissue-specific function in 3D culture (18) (19) (20) , while malignant cells form proliferative and invasive structures, which mimics the in vivo phenotypes of normal and tumor cells. These results indicate that 3D culture model is more physiologically relevant to study function and structure of malignant and nonmalignant mammary epithelial cells. In 3D culture model, the nonmalignant S1 cells form polarized spheroids, while their malignant counterpart T4-2 cells form disorganized structures. Furthermore, blocking b1-integrin, EGF receptor (EGFR), or matrix metalloproteinases (MMP) pathways reprograms T4-2 cells to form polarized and noninvasive acini-like structures [reverted T4-2 (T4R); refs. [20] [21] [22] . By analyzing the gene expression profiles of S1, T4-2 and T4R cells in 3D culture, we have identified many microenvironment-related genes that are differentially expressed in polarized and disorganized cells, including SEMA3F. SEMA3F is one of the microenvironmental factors with tumor suppressor function. This protein was first identified as a repulsive factor of axon guidance in neuron development by modulating cell polarization and migration (23, 24) . Expression of SEMA3F in cancer cells inhibits tumor growth, invasion, and metastasis through binding to its receptor, neuropilin (NRP) 1 and NRP2 (25, 26) . SEMA3F can also inhibit tumor angiogenesis by acting directly on vascular endothelial cells via NRP2 (27) . Thus, SEMA3F has been considered a potential therapeutic target that has the advantage of inhibiting both tumor cells and endothelial cells. Inactivation of SEMA3F during cancer development has been attributed to genomic instability because the SEMA3F gene locates at chromosome 3p21.3, which is commonly deleted in lung cancer (28) . In addition, a number of transcription factors (such as ZEB-1, p53, and ID-2) have been reported to regulate SEMA3F expression in lung, melanoma, and prostate cancer (29) (30) (31) . Nevertheless, how SEMA3F is suppressed in breast cancer remains to be determined.
We have identified RORa as a transcriptional regulator of the SEMA3F gene. We show that breast cancer development and progression is associated with inactivation of the RORa-SEMA3F pathway. Restoring RORa expression in breast cancer cells suppresses their malignant and invasive phenotypes in 3D culture and in the xenograft model. Reducing SEMA3F expression in RORa-expressing cells partially rescued the malignant phenotypes. These findings reveal that the RORa suppresses breast tumor invasiveness by modulating cell microenvironment.
Materials and Methods

Antibodies and reagents
Edu staining kit and Alexa Fluor 594 phalloidin were from Invitrogen. Matrigel (laminin-rich extracellular matrix, lrECM) and type I collagen were from BD Bioscience. RORA and SEMA3F cDNA clones were purchased from Open Biosystem. shRORA plasmids were purchased from Sigma. SMARTpool SEMA3F and nontargeting siRNA were purchased from Thermo Scientific. The following antibodies were obtained as indicated: RORa and Lamin A/C (Santa Cruz); tubulin, actin, and a6 intergrin (Millipore), Flag (Sigma); Ki-67 (Vector Laboratories). Phosphorylated Akt and Akt (Cell signaling); phosphorylated mitogen-activated protein/extracellular signal-regulated kinase (MEK) and MEK (Cell Signaling).
Cell culture and virus preparation
HMT-3522 S1 and T4-2 cells (a kind gift from Dr. Mina J. Bissell, Lawrence Berkeley National Laboratory, Berkeley, CA) were maintained on tissue culture plastic as previously described (17) . MDA-MB 231 cells (American Type Culture Collection) were propagated in Dulbecco's Modified Eagle's Medium (DMEM)/F12 (Sigma) with 10% FBS (Invitrogen). 3D lrECM) on-top cultures (32) were prepared by trypsinization of cells from tissue culture plastic, seeding of single cells on top of a thin gel of Engelbreth-Holm-Swarm (EHS) tumor extract (Matrigel: BD Biosciences), and addition of medium containing 5% EHS. S1 cells were seeded at a density of 3.1 Â 10 4 cells/cm 2 ; T4 and MDA-MB 231 cell lines were seeded at 2.1 Â 10 4 and 1.4
Â 10 4 cells/cm 2 . S1 and T4-2 cells were maintained in their propagation medium with media change every 2 days. MDA-MB 231 cells were maintained in H14 medium with 1% FBS.
Flag-tagged RORA cDNA and SEMA3F cDNA were cloned into pCDH1 plasmid and generated expression vector pCDH1-RORAl-Flag and pCDH1-SEMA3F-Flag. 293 FT cells were transfected with pCDH1 or shRNA vector (Sigma) plus packaging lentivector with lipofectamine (Invitrogen). Malignant and nonmalignant human mammary epithelial cell (HMEC) were infected with lentivirus and selected by puromycin 48 hours after infection.
Invasion and migration assay
The Transwells (Corning) were coated with 60 mL 1 mg/mL Matrigel and incubated for 30 minutes at 37 C. HEMCs were plated in 200 mL on top of the Transwell filter and incubated in 37 C 5% CO 2 for 24 hours. The invaded cells on the bottom face of the filter were fixed by methanol and stained with 8% crystal violet.
Vector control or RORa expression MDA-MB-231 cells (0.04 Â 10 6 ) were placed on type I collagen precoated 35 mm dishes in DMEM/F12 medium containing 2% FBS and 4 ng/mL EGF. After 2 hours incubation, at 37 C, images were taken by live cell/incubator imaging system (Nikon Biostation IMQ) every 10 minutes for 8 hours.
Luciferase report assay
A DNA fragment containing SEMA3F promoter region (from À1,513 to À1,240) was amplified from human genomic DNA with primers 5 0 -GCGGGTACCGCTGGAGATAGTGATAGAAG-TGGC-3 0 and 5 0 -GCGAAGCTTAGGTGAGCAAACACCATCCT-3 0 then cloned into luciferase report vector pGL4. A deletion (RORA response region from À1,372 to À1,360) mutant was constructed by primers 5 0 -CACTCATCTCCCTGAGGTCAC-CACCACTG-3 0 and 5 0 -ACCTCAGGGAGATGAGTGGGGAT-GAGGAG-3 0 . HEK 293 cells were transient transfected with pCDH1-RORA-Flag, pGL4-SEMA3F promoter, and Renilla luciferace vector. Cells lysate was collected for the luciferase assay 24 hours after transfection.
Immunofluorescence and immunohistochemistry
Cells in lrECM gel were smeared on slides, dried briefly, and fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. Immunostaining was carried out as previous described (18) . Stained samples were imaged with a Nikon upright epifluorescence microscope or a confocal system comprised of an Olympus IX81 microscope.
Tissue array (Biomax; Pantomics) and xenograft tumor sections were deparaffined and hydrated from xylene, 100% estrodial, 95% estrodial, 85% estrodial, and 70% estrodial to PBS solution. Endogeneous peroxidase was blocked by incubation with 3% H 2 O 2 for 20 minutes. Antigen retrieval was done by steaming in citrate sodium buffer for 30 minutes. Slides were incubated with antibodies at 4 C overnight, then the sections were incubated with goat anti-rabbit immunoglobulin G conjugated with horseradish peroxidase at room temperature for 60 minutes. The conjugated antibody was detected by diaminobenzidine, and images were taken by Nikon and scored blindly.
Western blot analysis and reverse transcriptase PCR Cells grown on plastic and filters were lysed in situ in RIPA buffer [1% Nonidet P-40, 0.5% deoxycholate, 0.2% SDS, 150 mmol/L sodium chloride, 50 mmol/L Tris HCl (pH 7.4) containing phosphatase and protease inhibitor cocktails (Calbiochem)]. Cells in 3D lrECM were isolated as colonies by ice-cold PBS plus 5 mmol/L EDTA and thereafter lysed in RIPA buffer as described previously (21) . Equal amounts of protein lysates were subjected to SDS gel electrophoresis, immunoblotted, and detected with an ECL system (Pierce).
Total RNA was extracted from cells with Trizol reagent (Invitrogen). cDNA was synthesized with SuperScript First Strand Synthesis kit (Invitrogen) from 0.5 to 1.0 mg RNA samples. cDNA synthesis was carried out with SuperScript III First-Strand Synthesis System according to the manufacturer's instructions. Quantitative reverse transcriptase PCR (RT-PCR) reactions were carried out using SYBR Green PCR master mix reagents on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). Thermal cycling was conducted at 95 C for 30 seconds, followed by 40 cycles of amplification at 95 C for 5 seconds, 55 C for 30 seconds, and 72 C for 15 seconds. The relative quantification of gene expression for each sample was analyzed by the DC t method. The following primers were used to amplify SEMA3F: 5 0 -CTTTACTTCTTCTTCCGT-GAGCG-3 0 and 5
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was conducted based on the Upstate Biotechnology ChIP protocol with a few modifications (18, 33) . After formaldehyde cross-linking, nuclei were isolated with a nuclei isolation kit (Sigma) and resuspended in ChIP lysis buffer (1% SDS, 10 mmol/L EDTA, 50 mmol/L Tris-HCl; pH8.0) containing protease inhibitor cocktail. Protein-DNA complexes were immunoprecipitated as per the Upstate protocol. Isolated DNA was then analyzed by quantitative PCR with the following primers: 5 0 -TGGAAGG-GATGGTGTTGGAAG-3 0 and 5 0 -ACAGGCAGGGCATTTGAG-GT-3 0 .
Xenograft experiment
Six-week-old female BalB/C null/null mice were randomly grouped and subcutaneously injected with 2 Â 10 6 control or RORa expression T4-2 cells (in PBS buffer, with 50% Matrigel). The control or RORa expression MDA-MB-231/Luc cells were injected into mammary fat pad at 2 Â 10 6 cells per gland of severe combined immunodeficient mice (SCID) mouse, and the tumor volume was measured with an in vivo imaging system (IVIS). All of the procedures during our study were carried out within the guidelines of the Division of Laboratory Animal Resources at the University of Kentucky. Tumors were measured with a caliper every 3 days for 3 weeks. After sacrificing all mice, the tumor samples were weighed, imaged, and fixed with 4% paraformaldehyde for section.
Kaplan-Meier survival analysis and other statistical analysis
We examined RORa expression in 404 breast tumor expression arrays taken from studies by Wang and colleagues (34; n ¼ 286) and Chin and colleagues (35; n ¼ 118). In each data set, the tumor samples were classified into RORa low [si (mean
, and RORa medium on the basis of RORa mRNA level. This method allowed us to compare relative RORa expression levels across both data sets fused as a single group of patients (36) . The association between RORa expression and clinical pathologic parameters was evaluated by the Fisher exact test. Significant differences in survival time were assessed with the Cox proportional hazard (log-rank) test. All reported P values were 2-tailed. Association between RORa and SEMA3F was evaluated by the Fisher exact test. Statistical analysis was conducted with SigmaPlot (Systat Software, Inc.) and SAS (version 9.2; SAS Institute Inc.).
Results
Reduced RORa expression is associated with disruption of polarized acinar structure and breast cancer development
To determine which genes are associated with cell polarization and acinar morphogenesis in 3D culture, we analyzed expression profiles of nonmalignant S1, malignant T4-2, and a variety of phenotypically reverted T4 cells (the cells are treated with a number of inhibitors targeted to EGFR, b1-integrin, or MMPs). Using Gene Set Enrichment Analyses (GSEA), we identified RORa as one of the transcription factors that induces gene expression in polarized S1 and T4R cells (Fig. 1A) . To determine whether RORa is differentially activated in polarized and disorganized HEMCs, we assessed RORa protein levels in S1, T4-2, and T4R cells in 3D culture. We found that both total and nuclear RORa levels were upregulated in polarized S1 and T4R cells compared with disorganized T4-2 cells (Fig. 1B) . This upregulation correlates with activation of the potential RORa-targeted genes. In addition, we carried out RT-PCR with isoform-specific primers to determine which RORa isoforms are expressed in HMECs. Only RORa1 and RORa4 transcripts were amplified from S1 and T4-2 cells (data not shown).
Breast cancer development is accompanied by disruption of tissue polarity; therefore, we next determined whether RORa expression is repressed in breast cancer cell lines and tissues. We assessed the protein levels of RORa in 12 malignant and nonmalignant HMECs cultured in 3D Matrigel. Results showed that protein expression of RORa was significantly reduced in breast cancer cells compared with nonmalignant cells (Fig. 1C) . Immunohistochemistry (IHC) analysis of a panel of normal and malignant breast tissues also showed that RORa protein expression was relatively downregulated in human breast cancer ( Fig. 1D and E) . By analyzing mRNA levels of RORa in published microarray data sets generated from more than 1,000 human malignant and nonmalignant breast tissues (37), we found that RORa transcription was significantly downregulated in cancer tissues (Supplementary Table S1 ).
Together these results indicate that breast cancer development is accompanied by reduced RORa expression.
RORa inhibits cell invasion and suppresses aggressive phenotypes of breast cancer cells
To explore the functional relevance of downregulation of RORa to malignant phenotypes of breast cancer cells, we restored RORa expression in T4-2 cells and examined their morphologies in 3D culture. T4-2 cells were infected with lentivirus-containing control or RORa-expressing vectors, and then expression of RORa was confirmed by Western blot (Fig.  2A) . RORa-expressing T4-2 cells formed round spheroid structures in 3D culture, and colony size was significantly reduced compared with the control cells ( Fig. 2B and Supplementary  Fig. S1 ). Staining with a6-integrin (basal marker) and Ki-67 antibodies revealed that RORa expression reprogrammed the cells to form polarized and growth-arrested structures (Fig. 2B, C, D) . It has been shown that activation of phosphoinositide 3-kinase (PI3K) and MEK pathways disrupts the polarized acinar structures and cell invasion (38) (39) (40) . Thus, we assessed the activity of these 2 pathways by measuring the phosphorylation of Akt and MEK. We found that restoring RORa expression in T4-2 cells reduced the levels of phosphorylated Akt and MEK (Fig. 2E) , suggesting that PI3K-Akt and MEK pathways are involved in RORa-regulated cell polarization. Because cell polarization is often associated with reduced invasiveness, we examined the invasiveness of RORa-expressing cells in the Transwell assay. Results showed that expression of RORa1 or RORa4 significantly inhibited invasion of T4-2 cells (Fig. 2F) .
To investigate the effect of RORa on tumor growth in vivo, the control and RORa1-expressing T4-2 cells were subcutaneously injected into the flanks of female athymic nude mice. We found that tumor growth was delayed in the RORa1 group compared with the control group (Fig. 2G) , and that the tumors formed by RORa1-expressing cells were significantly smaller Figure 1 . Expression of RORa is downregulated in breast cancer. A, GSEA analysis identified RORa as a potential regulator of the genes in which expression is significantly upregulated in polarized S1 and T4R cells compared with disorganized T4-2 cells. B, total and nuclear protein levels of RORa were examined by immunoblotting in T4-2, S1, and T4R cells. RORa level was downregulated in disorganized T4-2 cells compared with polarized S1 and T4R cells. C, RORa expression was examined by immunoblotting in malignant (8) than the tumors formed by control cells (Fig. 2H) . Ki-67 staining showed that the tumor cells in RORa1-expressing tumors were less proliferative than the cells in the control group (Fig. 2I) , which may cause the decrease of tumor volume in RORa-expressing tumors.
Restoring RORa expression in another breast cancer cell line, MDA-MB 231, also suppressed the aggressive phenotypes in 3D culture. For instance, the invasive branching structures and colony size were significantly reduced in RORa-expressing cells (Fig. 3A, B) ; cell proliferation and invasion were also significantly inhibited by RORa (Fig. 3C, D) . By tracking single-cell movement with live cell imaging, we also found that expression of RORa significantly inhibited cell migration in MDA-MB 231 cells (Fig. 3E, F) . Thus, reduction of invasive branching structures in RORa-expressing cells is most likely due to inhibition of cell migration and invasion. In addition, we have transplanted the control and RORa1-expressing MDA-MB 231 cells into the mammary gland fat pads of female SCID mice. We found that RORa1-expressing MDA-MB 231 cells formed much smaller tumor than control cells (Fig. 3G, H ).
Because disruption of acinar structure is accompanied by reduced RORa expression in 3D culture, we asked whether silencing RORa disturbs acinar morphogenesis in nonmalignant HMECs. S1 cells were infected with lentivirus-containing shRORa or control shRNA, and knockdown efficiency was assessed by Western blot (Fig. 4A ). The cells with reduced RORa expression formed disorganized structures with a slight increase in colony size compared with the control S1 cells in 3D culture (Fig. 4B, C) . Staining of a6-integrin showed that the number of polarized colonies is significantly decreased in the RORa knockdown cells (Fig. 4D) . These results indicate that RORa modulates polarization of HMECs, which is required for acinar morphogenesis.
SEMA3F is a RORa target gene and mediates its inhibitory activity on cell invasion
To understand how inactivation of RORa promotes breast tumor progression, we set out to identify RORa target genes mediating its suppressive activity in HMECs. SEMA3F, a secretary protein with tumor suppressor function (28) , is one of the potential RORa target genes identified by GSEA analysis. It has been shown that SEMA3F produced by cancer cell acts in a paracrine and autocrine manner inhibiting cell migration and invasion (25) (26) (27) . By analyzing protein in the conditional medium, we found that the secretion of SEMA3F is significantly upregulated in S1 and T4R compared with malignant T4-2 cells (Fig. 5A) , and restoring RORa expression in T4-2 cells enhanced the SEMA3F production (Fig. 5B) . The reduction of SEMA3F expression was also observed in breast cancer cell lines MDA-MB 231 and BT549 compared with nonmalignant MCF10A cells (Supplementary Fig. S2 ). To further verify whether SEMA3F is regulated by RORa at the transcription level, we measured the SEMA3F mRNA in RORa-expressing T4-2 and MDA-MB 231 cells. Quantitative RT-PCR results showed that SEMA3F transcription was induced by RORa in T4-2 and MDA-MB 231 cells (Fig. 5C) ; while knockdown of RORa in nonmalignant S1 cells significantly reduced SEMA3F transcription (Fig. 5D) .
By analyzing the genomic sequence of SEMA3F, we identified 2 potential RORa-binding sites from the proximal promoter region of SEMA3F (À1,372 to À1,360, À663 to À652). To verify whether RORa directly binds to these 2 regions, we carried out ChIP analysis. We found that binding of RORa to the À1,372 to À1,360 region was significantly enhanced in RORa-expressing T4-2 cells (Fig. 5E ), but little interaction was detected between RORa and the À663 to À652 region (data not shown). To assess whether RORa induces transcription of SEMA3F through this region, we amplified and cloned the SEMA3F promoter into pGL4 luciferase vector. The luciferase reporter construct was cotransfected with RORa expression vector into HEK293 cells. The activity of firefly/Renilla luciferase showed that expression of RORa1 drastically induced transcription driven by SEMA3F promoter (Fig. 5F ). To further verify whether the binding of RORa to this site is functionally important, the sequence from À1,372 to À1,360 was deleted in the SEMA3F promoter and cloned into the luciferase reporter construct. We found that deletion of the RORa binding site in the SEMA3F promoter significantly reduced the transcription activity (Fig. 5G) , indicating that binding of RORa to this region is critical for the transcriptional activation of SEMA3F.
To determine whether RORa-induced SEMA3F is functionally relevant to the suppressive activity of RORa in cancer cells, we silenced SEMA3F expression in RORa-expressing cancer cells with siRNA (Fig. 6A) . We found that knockdown of SEMA3F in RORa-expressing MDA-MB 231 cells rescued the invasive branch structure in 3D culture (Fig. 6B, C) . Moreover, silencing SEMA3F expression significantly enhanced cell invasion in RORa-expressing MDA-MB 231 and T4-2 cells. (Fig. 6D) . Next, we examined the activation of PI3K-Akt and MEK pathway in those cells. We found that downregulation of SEMA3F enhanced phosphorylation of MEK, but had little effects on Akt phosphorylation (Fig. 6E) . Because activation of MEK pathway has been shown to promote cancer invasion in culture and in vivo (40, 41) , these results suggest that the RORa-SEMA3F axis suppresses invasion of cancer cells through inhibiting MEK pathway. Moreover, RORa-expressing MDA-MB 231 cells tended to invade in surrounding tissue in SCID mice after SEMA3F was silenced, but knockdown of SEMA3F had little effect on tumor growth (Fig. 6F, G) . We also expressed SEMA3F in T4-2 and MDA-MB 231 cells. We found that the majority of SEMA3F-expressing cancer cells formed noninvasive structures in 3D culture ( Supplementary  Fig. S3 ). These results suggest that the tumor suppressor function of RORa is at least partially conferred by SEMA3F.
Reduced expression of RORa and SEMA3F is associated with poor prognosis
To address the clinical relevance of a functional link between RORa and SEMA3F, we examined protein and mRNA expression of RORa and SEAM3F in cohorts of human breast cancers. IHC analysis of a panel of 259 breast cancer tissues revealed that the nuclear levels of RORa significantly correlated to protein expression of SEMA3F (Fig. 7A and Table 1 ). Moreover, high grading tumors contain more RORa and SEMA3F double negative samples compared with low grading tumors ( Fig. 7B and Supplementary Table S2 ), suggesting that inactivation of RORa and SEMA3F is associated with breast cancer progression. To further determine whether reduced RORa or SEMA3F expression is associated with prognosis of patients, we assessed the association between mRNA levels of these 2 genes and patient survival using the published microarray data generated from more than 400 breast cancer tissue samples (34, 35) . Breast cancer patients were divided into 3 groups based on RORa or SEMA3F mRNA levels (low, moderate, and high). Kaplan-Meier log-rank analysis showed that patients whose tumor had low RORa or SEMA3F expression levels had a significantly shorter survival period (Fig. 7C, D) , suggesting that inactivation of the RORa-SEMA3F pathway correlates with poor clinical outcome.
Discussion
Disruption of acinar structures during breast cancer development is accompanied by the following 2 types of microenvironmental changes (42): (i) inhibiting suppressive microenvironmental signals, such as proper cell-cell and cell-basement membrane adhesion, MMP inhibitors, and suppressive microenvironmental factors (43); (ii) enhancing the promotional microenvironmental cues, including various growth factors and cytokines, ECM degradation enzymes, and activation of angiogenesis, which has been extensively studied and used as therapeutic target in clinical trials. By analyzing the global expression profiles of polarized and disorganized HMECs in 3D culture, we have identified a number of microenvironment-related genes downregulated in disorganized cells, including tumor suppressor SEMA3F. We show that RORa is a transcriptional regulator of SEMA3F and is repressed during breast cancer development and progression. Restoring RORa or SEMA3F expression in breast cancer cells inhibits aggressive phenotypes in 3D culture and tumor growth in vivo. We conclude that the RORa-SEMA3F axis provides a suppressive microenvironment in normal tissue, inactivation of which promotes breast cancer development and progression.
Loss of polarity is an important morphologic event in breast cancer development, which is accompanied by extensive . By searching for overrepresented motifs in the promoter regions of the differentially expressed genes between polarized and disorganized cells, we showed that RORa induces gene expression in polarized HMEC cells. We also show that expression of RORa protein is significantly reduced in breast cancer cell lines and cancer tissues, and this reduction is associated with disruption of the acinar structure in 3D culture and cancer progression in vivo. Silencing RORa expression in nonmalignant S1 cells disrupts the polarized acinar morphogenesis, suggesting that RORa is involved in normal mammary gland development. We also showed that restoring RORa expression in breast cancer cells significantly inhibits tumor growth in nude mice and suppressed malignant phenotypes in 3D culture. Furthermore, patients with reduced expression of RORa in cancer tissue have significantly shorter survival. Together these results indicate that inactivation of RORa promotes breast cancer development and progression by enhancing cell invasion and disturbing normal tissue architecture.
Microarray analysis has shown that RORa mRNA levels are downregulated in many types of cancer, including breast, lung, and colon (45) . Because the RORa gene locates at a common fragile site that is often deleted in cancer, it was proposed that inactivation or downregulation of RORa in cancer cells is caused by genomic instability. However, in the HMT-3522 breast cancer progression series, we showed that downregulation of RORa in cancer cells was reversible, suggesting that RORa is not regulated at the genomic level in those cell lines. We also analyzed the published microarray and CGH data generated from a panel of breast cancer cell lines (35) and did not find a correlation between RORa mRNA levels and gene copy numbers (data not shown). We showed that blocking the EGFR pathway with tryphostin significantly increased protein levels of RORa and mRNA levels of RORa target gene in T4-2 cells, whereas RORa mRNA level has little change upon inhibition of those pathways (data not shown). Therefore, it is most likely that RORa is regulated at the protein level in HMT-3,522 cell lines. Figure 5 . SEMA3F is an RORa target gene mediating its tumor suppressor function. A and B, SEMA3F secretion was assessed by Western blot in the conditional medium of S1, T4-2, T4R, and RORa-expressing T4-2 cells. Conditional medium isolated from same amount of cells was loaded, and SEMA3F levels were elevated in the medium of S1, T4R, and RORa-expressing T4-2 cells. C, quantitative RT-PCR measuring SEMA3F mRNA level in T4-2 and RORaexpressing T4-2 cells (n ¼ 4). D, quantitative RT-PCR measuring SEMA3F mRNA level in S1 and RORa knockdown S1 cells (n ¼ 6). E, ChIP analyzing protein enrichment in the SEMA3F promoter region in control and RORa-expressing T4-2 cells. Binding of RORa protein but not histone H3 to SEMA3F promoter was significantly enhanced in RORa-expressing T4-2 cells; n ¼ 3. F, luciferase assay measuring the transcriptional activity of SEMA3F promoter (from residues À1,513 to À1,240) in response to RORa expression. RORa1 enhanced promoter activity of SEMA3F in a dose-dependent manner; n ¼ 4. G, a deletion of RORE in SEMA3F promoter (from residues À1,372 to À1,360) was made and cloned into pGL4 vector. Promoter activity of SEMA3F in response to RORa was reduced by deletion of the RORE, n ¼ 4.
Ã , P < 0.05; ÃÃ , P < 0.01.
RORa has been considered a constitutively activated nuclear receptor, but a number of pathways are involved in posttranslational regulation of its activity. For instance, RORa can be phosphorylated by extracellular signal-regulated kinase (ERK) and PKC in neuron and HeLa cells. Both ERKand PKC-dependent phosphorylation suppresses the transcription activity of RORa (46, 47) . In addition, the RORa protein is rapidly turned over in Cos-1 cells, and the protein level increases upon inhibition of the 26S proteasome complexes (48) , indicating that the Ub-proteasome pathway is involved in degradation of RORa protein. A recent study sheds light on the roles of posttranslational modification of RORa in colon cancer development (6). Lee and colleagues showed that Wnt5a/PKCa induces phosphorylation on serine residue 35 of RORa. The phosphorylated RORa attenuates the Wnt signaling pathway through binding to b-catenin at Wnt3a-activatable promoters to suppress the transcription of Wnt/b-catenin target genes (6). Our results showed that deletion of the ligand-binding or DNA-binding domains in RORa drastically reduced the inhibitory activity of RORa (data not shown), thus we proposed that transcription activity of RORa is required for the tumor suppressor function in breast cancer. SEMA3F is one of the suppressive microenvironmental factors often inactivated in metastatic cancer, and the inactivation has been attributed to gene deletion in lung cancer (28) . Reduced mRNA levels of SEMA3F are associated with poor clinical outcome in breast cancer patients (Fig. 7D) , thus loss of SEMA3F function may contribute to breast cancer progression. We found that expression and secretion of SEMA3F are downregulated in disorganized HMECs compared with polarized cell in 3D culture, parallel to RORa inactivation. Using ChIP and luciferase reporter assays, we proved that SEMA3F is an RORa target gene. Although the tumor suppressor function of SEMA3F has been largely attributed to its antiangiogenesis activity, we showed that introducing SEMA3F in breast cancer cells suppressed the aggressive phenotypes in 3D culture, and knockdown of SEMA3F in RORa-expression cancer cells rescued cell invasiveness, suggesting that SEMA3F also targets breast cancer cells. In fact, SEMA3F receptor NRPs have been detected in breast cancer cells (49) , and it has been shown that expression of SEMA3F in breast cancer cells inhibits cell migration and invasion (50) . Mammary specific knockout of NRP2 impairs branch morphogenesis and ductal outgrowth in mouse mammary gland, suggesting that NRP2 is crucial for cell migration and invasion (51) . We show that SEMA3F receptor Fig. S4 ). Moreover, NRPs have been identified as coreceptors of integrin and VEGFR. Thus, SEMA3F may suppress breast cancer invasion and MEK phosphorylation by disturbing the interaction between NRPs and other receptors. However, silencing SEMA3F in RORa-expressing cancer cells has little effect on tumor growth, suggesting that the tumor suppressor function of RORa involves other target genes and pathways. We have identified multiple potential RORa target genes from the GSEA analysis, such as FBXW7 and ANGPT1, which have been shown to inhibit cell proliferation and cancer progression (52) (53) (54) . In myoblast cell line C2C12, RORa induces activation of the cdk-inhibitor p21 waF1/cipl, a marker for cell-cycle exit (55) . Wnt/b-catenin pathway has been linked to various types of cancers, including breast. Because RORa has been identified as an inhibitor of the Wnt signal, RORa may suppress breast tumor growth by inhibiting Wnt target genes. In addition, RORa negatively interferes with the NF-kB signaling pathway and suppresses inflammatory response by inducing IkBa (56) . These RORa target genes and pathways may also mediate inhibitory activities of RORa in breast cancer cells. Moreover, RORa has been identified as a transcriptional regulator of aromatase in MCF7 and T47D (57) and as a potential estrogen receptor (ER)a partner (58) , suggesting that RORa may have different target genes and functions in ER-positive cells. Therefore, it is important to address functional linkage between RORa Supplementary  Table S2 ). C and D, Kaplan-Meier survival analysis of breast cancer patients grouped by expression levels of RORa (C) and SEMA3F (D). The tumor samples were classified into low (RORa, n ¼ 114; SEMA3F, n ¼ 131), high (RORa, n ¼ 121; SEMA3F, n ¼ 124), and moderate (RORa, n ¼ 169; SEMA3F, n ¼ 149) based on the mRNA levels of RORa or SEMA3F in the published microarray data sets. Significant differences in survival time were calculated by the Cox proportional hazard (log-rank) test. and its target genes in different subtypes of breast cancer in the future.
In summary, our findings reveal that RORa is crucial for maintenance of a suppressive microenvironment in normal mammary tissue, and inactivation of RORa in breast cancer cells promotes cancer invasion by reducing SEMA3F expression. Thus, understanding how RORa is inactivated in breast cancer and identifying its ligands or agonists may lead to the discovery of a novel therapeutic strategy for the treatment of breast cancer.
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